Scarica l'app Stockscreener
1.83
0.81%
-0.015
Dopo l'orario di chiusura:
1.82
-0.01
-0.55%
Precedente Chiudi:
$1.845
Aprire:
$1.82
Volume 24 ore:
56,482
Relative Volume:
0.58
Capitalizzazione di mercato:
$3.31M
Reddito:
$12.99M
Utile/perdita netta:
$-27.83M
Rapporto P/E:
-0.00898
EPS:
-203.7366
Flusso di cassa netto:
$-26.98M
1 W Prestazione:
+7.02%
1M Prestazione:
-54.48%
6M Prestazione:
-64.81%
1 anno Prestazione:
-93.22%
Intervallo 1D:
$1.76
$1.88
Intervallo di 1 settimana:
$1.64
$1.99
Portata 52W:
$1.37
$48.78
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Nome
Aptevo Therapeutics Inc
Settore
Industria
Telefono
206-838-0500
Indirizzo
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
1.83 | 3.34M | 12.99M | -27.83M | -26.98M | -203.74 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-11-05 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-10-05 | Ripresa | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Borsa (APVO) Ultime notizie
APVO StockImmuno-Oncology Company To Watch Petersburg (cK2qyfq7CG) - mshale.com
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial - benzinga.com
Aptevo Therapeutics (NASDAQ: APVO) Registers 6.44M Shares for Holder Resale Following Warrant Exercises - Kalkine Media
Aptevo Therapeutics (APVO) Shares Fall Despite Roth Capital Opti - GuruFocus
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo reports 93% clinical benefit rate in AML trial subset By Investing.com - Investing.com Nigeria
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML - Yahoo Finance
Why is Aptevo Therapeutics stock slumping today? By Investing.com - Investing.com Canada
$Aptevo Therapeutics (APVO.US)$ [Strong][Smile][Heart][Rose][Leek] - Moomoo
Aptevo Therapeutics (APVO) Reports Promising AML Trial Results A - GuruFocus
Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML - TipRanks
Aptevo reports 93% clinical benefit rate in AML trial subset - Investing.com
Aptevo Reports Strong Mipletamig Results in TP53-Mutated AML - ACCESS Newswire
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML - FinancialContent
Aptevo Therapeutics Inc. SEC Filing (Sep 3, 2026) - Stock Titan
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Times Herald-Record
Aptevo Therapeutics Inc. (APVO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Aptevo Therapeutics (APVO) quietly closes private funding round - Stock Titan
Aptevo (APVO) Momentum: Moves 10.07% Down to $2.41 for the Current Session; Next Test: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingHagopian Line - vinanet.vn
APVO: Focusing on Three Key Areas of Development - Yahoo Finance
Aptevo Shareholders Back Board, Auditor and Incentive Plan - TipRanks
Aptevo (NASDAQ: APVO) asks holders to approve dilutive warrant deal - Stock Titan
Weekly Recap: APVO H1 losses and Aug 13 financing via warrants, PIPE - TradingView
Aptevo Therapeutics (APVO): CVI and Heights disclose 6.3% warrant-based stake - Stock Titan
Aptevo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aptevo Therapeutics Inc.: Financial Data Forecasts Estimates and Expectations | AP8 | US03835L3069 - marketscreener.com
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Aptevo Therapeutics Inc. 6M 2026: Net loss $(13.15M), Diluted EPS $(11.19) — 10-Q Summary - TradingView
Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - ACCESS Newswire
Aptevo Q2 Results: Cash at $9.8m, Mipletamig Advances - scanx.trade
Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing - TipRanks
Aptevo raises $4.5 million through warrant and equity financing By Investing.com - Investing.com Nigeria
Aptevo Raises $4.5 Million Via Warrant Exercises and PIPE; Issues 5.6M Warrants at $4.03 - TradingView
Aptevo raises $4.5 million through warrant and equity financing - Investing.com
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds - ACCESS Newswire
New Aptevo warrants for 4.3M shares await stockholder approval - Stock Titan
Aptevo Therapeutics Inc. (APVO) Stock: New Financing Targets $4.5M in Gross Proceeds - Blockonomi
Aptevo raises $4.5M through warrant exercises and private placement By Investing.com - Investing.com South Africa
Aptevo raises $4.5M through warrant exercises and private placement - Investing.com
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds - ACCESS Newswire
News by ACCESS Newswire on TradingView, 2026-08-12 - TradingView
Aptevo’s Common Warrants Cover Up to 4.3M Shares, Need Approval - Stock Titan
Aptevo Therapeutics (APVO) Rises 1.49% to $4.08, Approaches Resistance at $4.28Wave Equality - dars.gov.et
Aptevo Therapeutics (APVO) Holds Near $4.01 as Trading Range Narrows Between Support and ResistanceRetracement Entry - dars.gov.et
Aptevo Therapeutics (APVO) CMO converts RSUs; 156 shares withheld for taxes - Stock Titan
Aptevo Therapeutics (APVO) director converts 400 RSUs into 400 common shares - Stock Titan
Aptevo Therapeutics (APVO) director converts 400 RSUs into common shares - stocktitan.net
Aptevo Therapeutics (APVO) SVP SoYoung Kwon converts 638 RSUs to stock - Stock Titan
Aptevo Therapeutics (APVO) CFO exercises 638 RSUs into common stock - Stock Titan
Aptevo Therapeutics (APVO) director exercises RSUs, acquires 400 common shares - Stock Titan
Aptevo Therapeutics Inc Azioni (APVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):